Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by K Gupte-Singh
Cost-Effectiveness of Nivolumab (NIVO) Combined With Ipilimumab (IPI) Compared With Nivo and Ipi Monotherapies in the First-Line Treatment of Advanced Melanoma in the United States: Analysis Using 28-Month Overall Survival (OS) Data From Checkmate 067
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Related publications
Cost-Effectiveness of Nivolumab in Combination With Ipilimumab in First-Line Treatment of Advanced Melanoma in Sweden
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
A Phase III Study (CheckMate 238) of Adjuvant Immunotherapy With Nivolumab (NIVO) Versus Ipilimumab (IPI) After Complete Resection of Stage IIIb/c or Stage IV Melanoma (MEL) in Patients (Pts) at High Risk for Recurrence
Journal for ImmunoTherapy of Cancer
Oncology
Molecular Medicine
Pharmacology
Cancer Research
Allergy
Immunology
Pcn184 - Cost-Effectiveness of Nivolumab Plus Ipilimumab in Advanced Melanoma
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Ipilimumab Combined With Nivolumab: A Standard of Care for the Treatment of Advanced Melanoma?
Clinical Cancer Research
Cancer Research
Oncology
Pcn190 - Cost-Effectiveness of Nivolumab + Ipilimumab in First-Line Treatment of Advanced or Metastatic Renal Cell Carcinoma in the Netherlands
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
OA11 First-Line Nivolumab + Ipilimumab in Asian Patients With Advanced NSCLC and High TMB (≥10 Mut/Mb): Results From CheckMate 227
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P1.01-02 Long-Term Outcomes With First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 3-Year Follow-Up From CheckMate 012
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Pcn136 - A Cost-Effectiveness Analysis of Nivolumab in Combination With Ipilimumab for the Treatment of Advanced Renal Cell Carcinoma in Canada
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
P1.01-79 CheckMate 817: Safety of Flat-Dose Nivolumab Plus Weight-Based Ipilimumab for the First-Line (1L) Treatment of Advanced NSCLC
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
